BPH is a diversified company holding investments in biotechnology and resources. BPH holds a significant interest (22.3%) in unlisted oil and gas exploration company Advent Energy Ltd. BPH is commercialising a portfolio of Australian biomedical technologies emerging from collaborative research by leading universities, medical institutes and hospitals across Australia.
Biomedical technologies in the commercialisation stage include:
- Cortical Dynamics’ Brain Anaesthesia Response (BAR) Monitor; a device that measures a patient’s brain electrical activity (EEG) to indicate the response to drugs administered during surgery
- HLS5 Tumour Suppress Gene; a genetic marker for early and accurate cancer detection.
Advent Energy was formed in 2004 and is an unlisted oil and gas exploration and production company based in Perth, Western Australia. Advent has assembled an attractive portfolio of assets both on and offshore Australia that have had an estimated $81 million spent on historic exploration.
All permits are located next to a ready market and/or excellent infrastructure, thereby maximising Advent’s ability to optimise any resources. Included in the portfolio is: Petroleum Exploration Permit 11 in the offshore Sydney Basin. This permit has been assessed to contain several multi-Tcf targets adjacent to the major population region of Sydney and excellent port and power infrastructure. Retention Licence 1 (comprising the Weaber Gas Field), in the Onshore Bonaparte Basin. Near term development opportunities of conventional resources for local markets complements the unconventional shale gas resources recently revealed. Advent has a strong board with exceptional experience. Advent’s management and board members have over 75 years combined oil industry experience.
For more information on Advent Energy please visit www.adventenergy.com.au.